Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
The participants discussed the latest developments under ABDM that shall enable true interoperability in the health sector and how effective adoption of ABDM can pave the way towards Universal Health Coverage
Results reinforce commitment to next-generation oral SERD development programme
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
Subscribe To Our Newsletter & Stay Updated
